Ganirelix Acetate (BioDeep_00000839707)
代谢物信息卡片
Ganirelix Acetate
化学式: C84H121ClN18O17 (1688.8845166)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCNC(=NCCCCC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN=C(NCC)NCC)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC.CC(=O)O.CC(=O)O
InChI: 2*1-2(3)4/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89)
描述信息
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2092 - Gonadotropin Releasing Hormone Antagonist
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jody Paige Goh, Jill Cheng Sim Lee, Jerry Kok Yen Chan, John Carson Allen, Xiang Wen Ng, Sadhana Nadarajah, Jessie Wai Leng Phoon, Shuling Liu. The Effect of Luteinising Hormone Suppression in In Vitro Fertilisation Antagonist Cycles.
Reproductive sciences (Thousand Oaks, Calif.).
2021 11; 28(11):3164-3170. doi:
10.1007/s43032-021-00608-0. [PMID: 34076868] - Xiu Luo, Li Pei, Fujie Li, Chunli Li, Guoning Huang, Hong Ye. Fixed versus flexible antagonist protocol in women with predicted high ovarian response except PCOS: a randomized controlled trial.
BMC pregnancy and childbirth.
2021 May; 21(1):348. doi:
10.1186/s12884-021-03833-2. [PMID: 33934703] - Claudia Massarotti, Valentina La Pica, Fausta Sozzi, Paola Scaruffi, Valentino Remorgida, Paola Anserini. Influence of age on response to controlled ovarian stimulation in women with low levels of serum anti-Müllerian hormone.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
2020 Dec; 36(12):1074-1078. doi:
10.1080/09513590.2020.1737668. [PMID: 32148116] - Miguel Russo, Kimberly Liu, Crystal Chan. Suboptimal response to GnRH-agonist trigger during oocyte cryopreservation: a case series.
Reproductive biology and endocrinology : RB&E.
2020 Jun; 18(1):59. doi:
10.1186/s12958-020-00614-y. [PMID: 32503566] - Nigel Pereira, Jovana P Lekovich, Isaac Kligman, Zev Rosenwaks. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
2017 Aug; 33(8):593-597. doi:
10.1080/09513590.2017.1318372. [PMID: 28440686] - B Ozmen, Y E Sükür, M M Seval, C Ateş, C S Atabekoğlu, M Sönmezer, B Berker. Dual suppression with oral contraceptive pills in GnRH antagonist cycles for patients with polycystic ovary syndrome undergoing intracytoplasmic sperm injection.
European journal of obstetrics, gynecology, and reproductive biology.
2014 Dec; 183(?):137-40. doi:
10.1016/j.ejogrb.2014.10.033. [PMID: 25461367] - Vienna E Brunt, Jennifer A Miner, Paul F Kaplan, John R Halliwill, Lisa A Strycker, Christopher T Minson. Short-term administration of progesterone and estradiol independently alter carotid-vasomotor, but not carotid-cardiac, baroreflex function in young women.
American journal of physiology. Heart and circulatory physiology.
2013 Oct; 305(7):H1041-9. doi:
10.1152/ajpheart.00194.2013. [PMID: 23873800] - J H Check. Mild increases in serum FSH in late follicular phase increases the risk of the luteinized unruptured follicle: case report.
Clinical and experimental obstetrics & gynecology.
2013; 40(3):433-4. doi:
NULL. [PMID: 24283182] - N E Kummer, R S Feinn, D W Griffin, J C Nulsen, C A Benadiva, L L Engmann. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
Human reproduction (Oxford, England).
2013 Jan; 28(1):152-9. doi:
10.1093/humrep/des361. [PMID: 23077235] - Johannes D Veldhuis, Peter Y Liu, Paul Y Takahashi, Suanne M Weist, Jean R Wigham. Analysis of the impact of intravenous LH pulses versus continuous LH infusion on testosterone secretion during GnRH-receptor blockade.
American journal of physiology. Regulatory, integrative and comparative physiology.
2012 Nov; 303(10):R994-R1002. doi:
10.1152/ajpregu.00314.2012. [PMID: 22992702] - George T Lainas, Efstratios M Kolibianakis, Ioannis A Sfontouris, Ioannis Z Zorzovilis, George K Petsas, Theoni B Tarlatzi, Basil C Tarlatzis, Trifon G Lainas. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.
Reproductive biology and endocrinology : RB&E.
2012 Aug; 10(?):69. doi:
10.1186/1477-7827-10-69. [PMID: 22938051] - D Kyrou, M Al-Azemi, E G Papanikolaou, P Donoso, K Tziomalos, P Devroey, H M Fatemi. The relationship of premature progesterone rise with serum estradiol levels and number of follicles in GnRH antagonist/recombinant FSH-stimulated cycles.
European journal of obstetrics, gynecology, and reproductive biology.
2012 Jun; 162(2):165-8. doi:
10.1016/j.ejogrb.2012.02.025. [PMID: 22425288] - Juan Antonio García-Velasco, Sanja Kupesic, Antonio Pellicer, Claire Bourgain, Carlos Simón, Milan Mrazek, Paul Devroey, Joan-Carles Arce. Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial.
Reproductive biomedicine online.
2012 Feb; 24(2):153-62. doi:
10.1016/j.rbmo.2011.10.016. [PMID: 22197127] - Kevin J Doody, Paul Devroey, Arthur Leader, Han Witjes, Bernadette M Mannaerts. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa.
Reproductive biomedicine online.
2011 Oct; 23(4):449-56. doi:
10.1016/j.rbmo.2011.06.015. [PMID: 21856230] - Nicole Kummer, Claudio Benadiva, Richard Feinn, Jessica Mann, John Nulsen, Lawrence Engmann. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
Fertility and sterility.
2011 Jul; 96(1):63-8. doi:
10.1016/j.fertnstert.2011.04.050. [PMID: 21565337] - Laurel A Stadtmauer, Abbaa Sarhan, E Hakan Duran, Hind Beydoun, Silvina Bocca, Beth Pultz, Sergio Oehninger. The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: a prospective randomized study.
Fertility and sterility.
2011 Jan; 95(1):216-20. doi:
10.1016/j.fertnstert.2010.05.023. [PMID: 20594551] - B Katsoff, J H Check, C Wilson, J K Choe. Effect of serum progesterone level on the day of human chorionic gonadotropin injection on outcome following in vitro fertilization-embryo transfer in women using gonadotropin releasing hormone antagonists.
Clinical and experimental obstetrics & gynecology.
2011; 38(4):322-3. doi:
NULL. [PMID: 22268263] - Devrim Ertunc, Ekrem C Tok, Aysun Savas, Ilay Ozturk, Saffet Dilek. Gonadotropin-releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.
Fertility and sterility.
2010 Mar; 93(4):1179-84. doi:
10.1016/j.fertnstert.2008.11.030. [PMID: 19200979] - Cem Ficicioglu, Banu Kumbak, Oya Akcin, Rukset Attar, Gazi Yildirim, Narter Yesildaglar. Comparison of follicular fluid and serum cytokine concentrations in women undergoing assisted reproductive treatment with GnRH agonist long and antagonist protocols.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
2010 Mar; 26(3):181-6. doi:
10.1080/09513590903215557. [PMID: 19718559] - J Martinez-Salazar, M Cerrillo, G Quea, A Pacheco, J A Garcia-Velasco. GnRH antagonist ganirelix prevents premature luteinization in IUI cycles: rationale for its use.
Reproductive biomedicine online.
2009 Aug; 19(2):156-61. doi:
10.1016/s1472-6483(10)60066-1. [PMID: 19712548] - David R Meldrum, Richard T Scott, Michael J Levy, Michael M Alper, Nicole Noyes. Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss.
Fertility and sterility.
2009 May; 91(5):1963-5. doi:
10.1016/j.fertnstert.2008.01.007. [PMID: 18339377] - Young-Ah Koo, BoEun Lee, Hyun-Jung Park, JongYeob Choi, EunYoung Lee, DooSeok Choi. Altered vascular endothelial growth factor expression during GnRH antagonist protocol in women of reproductive age with normal baseline hormone profiles.
Fertility and sterility.
2009 Mar; 91(3):744-8. doi:
10.1016/j.fertnstert.2007.12.068. [PMID: 18321491] - J H Check, D Brasile, J K Choe, J Amui, C Wilson. The effect of cetrorelix vs. ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum follicle stimulating hormone levels.
Clinical and experimental obstetrics & gynecology.
2009; 36(3):148-9. doi:
NULL. [PMID: 19860353] - Nina S Stachenfeld. Sex hormone effects on body fluid regulation.
Exercise and sport sciences reviews.
2008 Jul; 36(3):152-9. doi:
10.1097/jes.0b013e31817be928. [PMID: 18580296] - Lawrence Engmann, Andrea DiLuigi, David Schmidt, John Nulsen, Donald Maier, Claudio Benadiva. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Fertility and sterility.
2008 Jan; 89(1):84-91. doi:
10.1016/j.fertnstert.2007.02.002. [PMID: 17462639] - K Aleksandrov, G Kozovski, E Kovachev, M Angelova, V Markova, I Kozovski. [Ovulation induction in high risk IVF patients: GnRH-agonist, diminished dose of urinary or recombinant chorion gonadotropin].
Akusherstvo i ginekologiia.
2008; 47(5):3-6. doi:
NULL. [PMID: 19230256] - Porntip Sirayapiwat, Somchai Suwajanakorn, Surang Triratanachat, Somchai Niruthisard. The effects of GnRH antagonist on the endometrium of normally menstruating women.
Journal of assisted reproduction and genetics.
2007 Dec; 24(12):579-86. doi:
10.1007/s10815-007-9184-z. [PMID: 18049889] - T G Lainas, I A Sfontouris, I Z Zorzovilis, G K Petsas, G T Lainas, E M Kolibianakis. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist.
Reproductive biomedicine online.
2007 Oct; 15(4):408-12. doi:
10.1016/s1472-6483(10)60366-5. [PMID: 17908403] - Nina S Stachenfeld, Hugh S Taylor. Exogenous oestradiol and progesterone administration does not cause oedema in healthy young women.
Clinical endocrinology.
2007 Mar; 66(3):410-8. doi:
10.1111/j.1365-2265.2007.02748.x. [PMID: 17302877] - Robert L Gustofson, James H Segars, Frederick W Larsen. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.
Human reproduction (Oxford, England).
2006 Nov; 21(11):2830-7. doi:
10.1093/humrep/del059. [PMID: 16966348] - Asimina Tavaniotou, Paul Devroey. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles.
Reproductive biomedicine online.
2006 Sep; 13(3):326-30. doi:
10.1016/s1472-6483(10)61435-6. [PMID: 16984758] - Robert L Gustofson, Frederick W Larsen, Mark R Bush, James H Segars. Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome.
Fertility and sterility.
2006 Jan; 85(1):251-4. doi:
10.1016/j.fertnstert.2005.07.1291. [PMID: 16412770] - F P Hohmann, J S E Laven, A G M G J Mulders, J J L Oberyé, B M J L Mannaerts, F H de Jong, B C J M Fauser. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
Journal of endocrinological investigation.
2005 Dec; 28(11):990-7. doi:
10.1007/bf03345337. [PMID: 16483177] - I E Messinis, D Loutradis, E Domali, C P Kotsovassilis, L Papastergiopoulou, A Kallitsaris, P Drakakis, K Dafopoulos, S Milingos. Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment.
Human reproduction (Oxford, England).
2005 Nov; 20(11):3192-7. doi:
10.1093/humrep/dei210. [PMID: 16037104] - Peter Y Liu, Paul Y Takahashi, Pamela D Roebuck, Ali Iranmanesh, Johannes D Veldhuis. Aging in healthy men impairs recombinant human luteinizing hormone (LH)-stimulated testosterone secretion monitored under a two-day intravenous pulsatile LH clamp.
The Journal of clinical endocrinology and metabolism.
2005 Oct; 90(10):5544-50. doi:
10.1210/jc.2005-0909. [PMID: 16030163] - Shin Yong Moon, Seung-Yup Ku, Sun Mie Kim, Byung Chul Jee, Chang Suk Suh, Young Min Choi, Jung Gu Kim, Seok Hyun Kim. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
The journal of obstetrics and gynaecology research.
2005 Jun; 31(3):227-35. doi:
10.1111/j.1447-0756.2005.00277.x. [PMID: 15916659] - N Prapas, Y Prapas, Y Panagiotidis, S Prapa, P Vanderzwalmen, R Schoysman, G Makedos. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study.
Human reproduction (Oxford, England).
2005 Jun; 20(6):1516-20. doi:
10.1093/humrep/deh832. [PMID: 15860501] - Paul Y Takahashi, Peter Y Liu, Pamela D Roebuck, Ali Iranmanesh, Johannes D Veldhuis. Graded inhibition of pulsatile luteinizing hormone secretion by a selective gonadotropin-releasing hormone (GnRH)-receptor antagonist in healthy men: evidence that age attenuates hypothalamic GnRH outflow.
The Journal of clinical endocrinology and metabolism.
2005 May; 90(5):2768-74. doi:
10.1210/jc.2004-2521. [PMID: 15741251] - P A Flierman, J J L Oberyé, V P M van der Hulst, S de Blok. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix.
BJOG : an international journal of obstetrics and gynaecology.
2005 May; 112(5):638-42. doi:
10.1111/j.1471-0528.2004.00504.x. [PMID: 15842290] - Daniel B Shapiro, Dorothy Mitchell-Leef, Melinda Carter, Zsolt Peter Nagy. Ganirelix acetate use in normal- and poor-prognosis patients and the impact of estradiol patterns.
Fertility and sterility.
2005 Mar; 83(3):666-70. doi:
10.1016/j.fertnstert.2004.11.001. [PMID: 15749496] - Larry I Barmat, Samuel J Chantilis, Bradley S Hurst, Richard P Dickey. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
Fertility and sterility.
2005 Feb; 83(2):321-30. doi:
10.1016/j.fertnstert.2004.06.076. [PMID: 15705369] - R Stan Williams, Jessica B Hillard, Gary De Vane, Tim Yeko, Simon Kipersztok, Alice Rhoton-Vlasak, Chris Sistrom. A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy.
American journal of obstetrics and gynecology.
2004 Aug; 191(2):648-51; discussion 651. doi:
10.1016/j.ajog.2004.06.072. [PMID: 15343256] - Barbara Sonntag, Ludwig Kiesel, Eberhard Nieschlag, Hermann M Behre. Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing gnRH agonist versus antagonist protocols for ovarian hyperstimulation.
Journal of assisted reproduction and genetics.
2004 Jul; 21(7):249-55. doi:
10.1023/b:jarg.0000042010.86102.03. [PMID: 15526982] - Christopher R McCartney, Amy B Bellows, Melissa B Gingrich, Yun Hu, William S Evans, John C Marshall, Johannes D Veldhuis. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome.
American journal of physiology. Endocrinology and metabolism.
2004 Jun; 286(6):E902-8. doi:
10.1152/ajpendo.00415.2003. [PMID: 14736706] - Nina S Stachenfeld, Hugh S Taylor. Effects of estrogen and progesterone administration on extracellular fluid.
Journal of applied physiology (Bethesda, Md. : 1985).
2004 Mar; 96(3):1011-8. doi:
10.1152/japplphysiol.01032.2003. [PMID: 14660504] - Henk J Out, Anthony Rutherford, Richard Fleming, Clement C K Tay, Geoffrey Trew, William Ledger, David Cahill. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction.
Human reproduction (Oxford, England).
2004 Jan; 19(1):90-5. doi:
10.1093/humrep/deh044. [PMID: 14688163] - J M Weiss, B Krautmacher, S Polack, K Diedrich, O Ortmann. Actions of GnRH antagonists on IGF-II, IGF-binding protein-2 and pregnancy-associated plasma protein-A in human granulosa-lutein cells.
European journal of endocrinology.
2003 Jul; 149(1):31-7. doi:
10.1530/eje.0.1490031. [PMID: 12824863] - Karen E Elkind-Hirsch, Bobby W Webster, Crystal P Brown, Michael W Vernon. Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome.
Fertility and sterility.
2003 Mar; 79(3):603-7. doi:
10.1016/s0015-0282(02)04696-4. [PMID: 12620447] - Human Mousavi Fatemi, Peter Platteau, Carola Albano, André Van Steirteghem, Paul Devroey. Rescue IVF and coasting with the use of a GnRH antagonist after ovulation induction.
Reproductive biomedicine online.
2002 Nov; 5(3):273-5. doi:
10.1016/s1472-6483(10)61832-9. [PMID: 12470526] - Mohamed F M Mitwally, Robert F Casper. Effect of in vivo GnRH agonist and GnRH antagonist on hCG and insulin-stimulated progesterone production by human granulosa-lutein cells in vitro.
Journal of assisted reproduction and genetics.
2002 Aug; 19(8):384-9. doi:
10.1023/a:1016398405248. [PMID: 12182445] - B C Fauser, D de Jong, F Olivennes, H Wramsby, C Tay, J Itskovitz-Eldor, H G van Hooren. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
The Journal of clinical endocrinology and metabolism.
2002 Feb; 87(2):709-15. doi:
10.1210/jcem.87.2.8197. [PMID: 11836309] - K Gordon. Gonadotropin-releasing hormone antagonists implications for oocyte quality and uterine receptivity.
Annals of the New York Academy of Sciences.
2001 Sep; 943(?):49-54. doi:
10.1111/j.1749-6632.2001.tb03789.x. [PMID: 11594557] - NULL. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
Human reproduction (Oxford, England).
2001 Apr; 16(4):644-51. doi:
10.1093/humrep/16.4.644. [PMID: 11278211] - D de Jong, N S Macklon, M J Eijkemans, B M Mannaerts, H J Coelingh Bennink, B C Fauser. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
Fertility and sterility.
2001 Apr; 75(4):688-93. doi:
10.1016/s0015-0282(00)01789-1. [PMID: 11287020] - J Itskovitz-Eldor, S Kol, B Mannaerts. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Human reproduction (Oxford, England).
2000 Sep; 15(9):1965-8. doi:
10.1093/humrep/15.9.1965. [PMID: 10966996] - G Borm, B Mannaerts. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Human reproduction (Oxford, England).
2000 Jul; 15(7):1490-8. doi:
10.1093/humrep/15.7.1490. [PMID: 10875855] - J Oberyé, B Mannaerts, J Huisman, C Timmer. Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran) administration by Medi-Jector compared to conventional needle injections.
Human reproduction (Oxford, England).
2000 Feb; 15(2):245-9. doi:
10.1093/humrep/15.2.245. [PMID: 10655292] - J J Oberyé, B M Mannaerts, J A Huisman, C J Timmer. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers.
Fertility and sterility.
1999 Dec; 72(6):1006-12. doi:
10.1016/s0015-0282(99)00414-8. [PMID: 10593372] - J J Oberyé, B M Mannaerts, H J Kleijn, C J Timmer. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers.
Fertility and sterility.
1999 Dec; 72(6):1001-5. doi:
10.1016/s0015-0282(99)00413-6. [PMID: 10593371] - NULL. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Human reproduction (Oxford, England).
1998 Nov; 13(11):3023-31. doi:
10.1093/humrep/13.11.3023. [PMID: 9853849] - D de Jong, N S Macklon, B M Mannaerts, H J Coelingh Bennink, B C Fauser. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization.
Human reproduction (Oxford, England).
1998 Mar; 13(3):573-5. doi:
10.1093/humrep/13.3.573. [PMID: 9572414] - V Y Fujimoto, S E Monroe, L R Nelson, D Downey, R B Jaffe. Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray.
Fertility and sterility.
1997 Mar; 67(3):469-73. doi:
10.1016/s0015-0282(97)80071-4. [PMID: 9091332] - L R Nelson, V Y Fujimoto, R B Jaffe, S E Monroe. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix).
Fertility and sterility.
1995 May; 63(5):963-9. doi:
10.1016/s0015-0282(16)57531-1. [PMID: 7536693] - C Nerenberg, J LaFargue, C Gee, F Chu, L Wolfe, R Chan, T Tarnowski. Radioimmunoassay of ganirelix in plasma or serum.
Journal of immunoassay.
1993 Sep; 14(3):191-207. doi:
10.1080/15321819308019849. [PMID: 8354719] - J Rabinovici, P Rothman, S E Monroe, C Nerenberg, R B Jaffe. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women.
The Journal of clinical endocrinology and metabolism.
1992 Nov; 75(5):1220-5. doi:
10.1210/jcem.75.5.1385467. [PMID: 1385467] - R L Chan, S C Hsieh, P E Haroldsen, W Ho, J J Nestor. Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration.
Drug metabolism and disposition: the biological fate of chemicals.
1991 Sep; 19(5):858-64. doi:
NULL. [PMID: 1686228]